Who has invested in Abivax?

Truffle Capital are named among the investors backing Abivax.

Abivax Funding: $204M Raised, IPO (2025)

Abivax funding overview

Abivax is a Biotech company based in Paris, France. Abivax has raised $204M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is an IPO announced in July 2025. The round record for Abivax runs through 2025; nothing later has been disclosed. Investors on record include Truffle Capital.

Abivax at a glance

Total raised: $204M
Latest round: IPO
Latest round date: July 2025
Industry: Biotech
Headquarters: Paris, France
Notable investors: Truffle Capital

Frequently asked about Abivax funding

How much has Abivax raised?: Abivax has raised $204M in total disclosed funding across the rounds on record.
Who has invested in Abivax?: Truffle Capital are named among the investors backing Abivax.
What was the latest Abivax funding round?: The most recent disclosed round is an IPO, announced in July 2025.
Where is Abivax based?: Abivax is based in Paris, France.
What sector does Abivax operate in?: Abivax is tracked under Biotech from Paris, France, with $204M in disclosed funding.
When did Abivax last raise?: The last disclosed Abivax round closed in July 2025 at IPO.

Abivax totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related Biotech companies in Paris below to benchmark round size and investor mix.

Abivax Funding: $204M Raised, IPO (2025)

Abivax funding overview

Abivax at a glance

Frequently asked about Abivax funding

Companies related to Abivax (37)

Browse related funding lists (5)